Related Experiment Video
Updated: Jun 1, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Haemophilia management: time to get personal?
T E Howard1, C Yanover, J Mahlangu
1Department of Pathology and Laboratory Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. tom.howard@va.gov
Summary
Alloimmunization risk during protein replacement therapy hinges on three factors: protein structural differences, patient immune system variations (HLA genes), and immune danger signals. Understanding these can personalize therapies for genetic disorders.
Area of Science:
- Immunology
- Pharmacology
- Genetics
Background:
- Protein replacement therapy (PRT) is crucial for genetic disorders.
- Alloimmunization, an immune response against therapeutic proteins, can reduce treatment efficacy.
- Identifying risk factors for alloimmunization is essential for patient safety and treatment optimization.
Purpose of the Study:
- To elucidate the key risk factors contributing to alloimmunization in patients undergoing protein replacement therapy.
- To explore the interplay between therapeutic protein characteristics, host immune genetics, and immune signaling in alloimmunization.
- To lay the groundwork for personalized therapeutic protein strategies.
Main Methods:
- Analysis of structural differences between therapeutic and endogenous proteins.
- Evaluation of recipient genetic variations, particularly HLA gene polymorphisms influencing antigen presentation.
- Consideration of immunologic danger signals during antigen presentation by antigen-presenting cells (APCs).
Main Results:
- Alloimmunization risk is multifactorial, requiring the confluence of three specific risk factors.
- Therapeutic protein structure, patient HLA genotype, and immune danger signals are critical determinants.
- The degree of structural divergence between therapeutic and endogenous proteins is a primary risk factor.
Conclusions:
- Personalized protein replacement therapies can be developed by assessing individual risk factors.
- Understanding protein structure and patient immune genetics is key to minimizing immunogenicity.
- Future strategies may involve tailoring therapeutic proteins to specific patient profiles, such as in hemophilia A and B.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:05Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...